Search Results

By Robert Rifkin, MD, FACP, Guest Editor  / November 10, 2016 - Supplement: Biosimilars in Oncology

Introduction

As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...